Model parameters and outcome measures of three post-SE models of TLE that are currently used for antiepileptogenic drug discovery in the authors' laboratory
See section III.C.3.g for details.
| Post-SE TLE Model in Rats | |||
|---|---|---|---|
| Lithium-Pilocarpine (Systemic Administration of Pilocarpine with Ramping Design for Individual Dosing) | Unilateral Electrical Stimulation of Basolateral Amygdala | Unilateral Intrahippocampal Injection of Kainate | |
| Duration of SE for inducing SRS | ≥60 min | ≥4 h | ≥4 h |
| Effective interruption of SE by | Diazepam + phenobarbital | Diazepam | Diazepam |
| Latent period | ∼7 days | ∼30 days | ? |
| Rats with spontaneous recurrent seizures | >90% | >90% | >90% |
| Neuropathology | Bilateral, widespread | Mostly unilateral, less widespread | Mostly unilateral, less widespread |
| Antiepileptogenic drug testing | |||
| Start of drug administration | Immediately after termination of SE | ||
| Duration of drug administration | At least 2 weeks | ||
| Dosing interval | Depends on elimination rate of test drug in rats | ||
| Outcome measures | Latent period to first spontaneous seizure; Incidence, frequency, severity, and duration of spontaneous seizures; Surrogate measures, including preictal and interictal spikes, ripples, seizure threshold; Behavioral alterations; Learning and memory; Hippocampal field potentials; Brain imaging (μMRI); Postmortem (immuno)histology | ||
SRS, spontaneous recurrent seizures.